Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial. Issue 3 (23rd September 2021)

• Record Type: Journal Article
• Authors: Bolhuis, Karen; Grosheide, Lodi; Wesdorp, Nina J.; Komurcu, Aysun; Chapelle, Thiery; Dejong, Cornelis H. C.; Gerhards, Michael F.; Grünhagen, Dirk J.; van Gulik, Thomas M.; Huiskens, Joost; De Jong, Koert P.; Kazemier, Geert; Klaase, Joost M.; Liem, Mike S. L.; Molenaar, I. Quintus; Patijn, Gijs A.; Rijken, Arjen M.; Ruers, Theo M.; Verhoef, Cornelis; de Wilt, Johannes H. W.; Punt, Cornelis J. A.; Swijnenburg, Rutger-Jan
• Other Names: other.
• Is Part Of: Annals of surgery open. Volume 2:Issue 3(2021)
• Page Start: e081
• Publication Date: 2021-09-23
• Subjects: ablation -- colorectal cancer -- colorectal liver metastases -- mortality -- postoperative morbidity -- resection -- surgery; Surgery -- Periodicals; Surgery -- History -- Periodicals; General Surgery; Surgery; History; Periodicals; 616
• DOI: 10.1097/AS9.0000000000000081
• Languages: English
• ISSNs: 2691-3593

Abstract

Abstract : Objective: To present short-term outcomes of liver surgery in patients with initially unresectable colorectal liver metastases (CRLM) downsized by chemotherapy plus targeted agents. Background: The increase of complex hepatic resections of CRLM, technical innovations pushing boundaries of respectability, and use of intensified induction systemic regimens warrant for safety data in a homogeneous multicenter prospective cohort. Methods: Patients with initially unresectable CRLM, who underwent complete resection after induction systemic regimens with doublet or triplet chemotherapy, both plus targeted therapy, were selected from the ongoing phase III CAIRO5 study (NCT02162563). Short-term outcomes and risk factors for severe postoperative morbidity (Clavien Dindo grade ≥ 3) were analyzed using logistic regression analysis. Results: A total of 173 patients underwent resection of CRLM after induction systemic therapy. The median number of metastases was 9 and 161 (93%) patients had bilobar disease. Thirty-six (20.8%) 2-stage resections and 88 (51%) major resections (>3 liver segments) were performed. Severe postoperative morbidity and 90-day mortality was 15.6% and 2.9%, respectively. After multivariable analysis, blood transfusion (odds ratio [OR] 2.9 [95% confidence interval (CI) 1.1–6.4], P = 0.03), major resection (OR 2.9 [95% CI 1.1–7.5], P = 0.03), and triplet chemotherapy (OR 2.6 [95% CI 1.1–7.5], P = 0.03) were independently correlated with severe postoperative complications. No association was found between number of cycles of systemic therapy and severe complications ( r = −0.038, P = 0.31). Conclusion: In patients with initially unresectable CRLM undergoing modern induction systemic therapy and extensive liver surgery, severe postoperative morbidity and 90-day mortality were 15.6% and 2.7%, respectively. Triplet chemotherapy, blood transfusion, and major resections were associated with severe postoperative morbidity.